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Storage and secondary use of bloodspots collected for newborn screening raises 
controversies because of the particularly sensitive nature of the information that can 
be derived from them and the lack of national standards and consistent provincial 
policies that can serve to guide storage facilities. This report, derived through a review 
of Canadian and provincial policy statements, a survey of provincial newborn 
screening laboratory directors and program directors, as well as through a consultative 
workshop, illustrates the social, ethical and legal issues regarding the storage, access 
and further uses of newborn bloodspots. The report indicates that there is a need for 
heightened transparency and clear recommendations concerning the criteria for 





Newborn screening (NBS) for serious treatable metabolic disorders has been 
standard-of-care in North America, Australia and Europe for over 40 years. Several 
tests can be done with just a few drops of blood from a baby’s heel dried onto filter 
paper (the “blood spot card”). After testing is completed, the remaining blood spot 
card is usually stored. Recently, stored blood spot cards have been considered useful 
for a variety of other purposes.1,2 In particular, the research potential of stored 
newborn bloodspots and the standard practices regarding storage of dried bloodspots 
have become a source of debate and concern.3,4 The main purpose of NBS programs 
has been diagnosis and early treatment of the newborn. Thus, caution has been 
expressed against the risk that storage of bloodspots may compromise the important 
traditional public health benefits of the screening program. Considering that NBS 
programs are perceived as routine paediatric practice in many countries and parental 
consent is usually implied, the existence of such specimen banks raises issues of 
privacy and confidentiality.5 Regarding consent for storage and other uses, parents are 
being approached at a particularly vulnerable time. It is not clear whether they can 
distinguish the clinical purposes from consent required for storage and research 
purposes.6 Moreover, parental views on the topic of the retention and use of screening 
samples are largely unknown.7 
 
Use of dried bloodspots for purposes unrelated to the initial collection has the 
potential to bring health benefits to both families and health providers.8 These blood 
samples are valuable for research to study: gene frequencies in the population;9 risk 
factors for birth defects or developmental problems;10 public health surveillance to 
determine for example HIV prevalence in newborns;11 and sometimes, for non-
medical purposes by helping identify disaster victims.12 In addition, because DNA is 
a very stable compound and can be stored for a long period of time and re-analysed at 
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any time, these samples may be valuable to validate new screening tools and for 
clinical tests of genetic diseases.13 
 
Nevertheless, because of the particularly sensitive nature of the information that can 
be derived from the newborn bloodspots, there is a need to consider the social, ethical, 
and legal acceptability of storage. In fact, concerns have been expressed about the 
potential misuse of the information by insurance companies and other third parties, 
including schools, governmental agencies, immigration departments and future 
employers.14 There are familial implications since the information may be used for 
health related reproductive choices.15,16 There are also concerns about the 
vulnerability of young persons17 and the possible psycho-social impact for the child 
growing up with risk information.18 Hence, careful planning and policies are required 
to protect stored newborn bloodspots. 
 
A number of complex and challenging issues arise related to the justification for the 
storage and secondary use, possible data sharing, privacy and confidentiality, 
informed consent, the information to be imparted to parents, and implications for 
health care resources. The sensitive nature of the information introduces compelling 
questions. For example: When is storage justified and for what purposes? Who has 
access to the data derived from the bloodspots? Should explicit parental consent be 
sought for research using bloodspots? If parental consent is sought, how and when 
should this be obtained? What information should be provided to parents concerning 
the storage and future use of dried bloodspots? What are the costs associated with 
storage? Should there be a common centralised repository?  
 
Internationally, a review of policy statements addressing storage reveals there is 
currently a lack of clear and consistent policies regarding the storage of newborn 
bloodspots.19 This lack of agreement is no different across the Canadian provinces. In 
Canada, universal NBS is a matter of provincial jurisdiction. As a result depending on 
the province, newborn bloodspots are currently stored for variable periods of time in 
order to permit confirmatory diagnosis, re-testing (if necessary), and quality control. 
The storage of dried bloodspots for these purposes is not particularly controversial 
and consent for such storage is usually considered to be implied (similar to the 
original newborn screening where consent is implied) since these uses are related to 
the primary purpose of the initial collection, namely screening newborns for various 
disorders. 
 
Nevertheless, as mentioned above, storage raises controversies because of the 
particularly sensitive nature of the information that can be derived from them and 
because of the lack of national standards and consistent provincial policies that can 
serve to guide storage facilities. It is in this context that we set out to: a) determine the 
current practices related to the storage of newborn bloodspots in Canada; b) review 
and analyse the NBS policies that were in place at the time of the survey, and c) 
explore with a multidisciplinary group of stakeholders the social, ethical and legal 
dimensions of their concerns related to the storage and use of newborn bloodspots.  
 
This paper sets out key issues identified during the survey and the consultative 
workshop regarding the policies and socio-ethical concerns associated with the 
storage of newborn bloodspots in Canada. It concludes by highlighting the potential 
 
Genomics, Society and Policy, Vol.2 No.3 (2006) ISSN: 1746-5354 
© ESRC Genomics Network.
            Genomics, Society and Policy 
            2006, Vol.2, No.3, pp.80-95 
 
_____________   82 
and existing bioethical challenges thus laying the groundwork for the development of 




We sought information about the social, ethical and legal aspects that address the 
storage, access and further uses of bloodspots from the following sources: a) a review 
of Canadian and provincial policy statements; b) a survey of provincial NBS 
laboratory Directors and NBS program Directors; c) a consultative workshop. 
 
a) Policy Statements Newborn Screening 
 
Directors of provincial NBS laboratories and NBS programs were asked to provide 
written copies of their existing guidelines or documents related to NBS. We analysed 
four relevant documents focusing on the storage of bloodspots and checked what 




A questionnaire was developed by the principal investigators and pilot-tested with 
experts in the field. In February 2005, the survey was sent to the Directors of 
provincial newborn screening laboratories and provincial NBS committees. These 
individuals were usually clinicians or clinical biochemists closely involved in the 
management of the laboratory. Information was collected via a self-administered e-
mail survey and follow-up with phone calls to encourage a response. Items in the 
questionnaire focused on four key areas: written policies and program material; length 
and purpose of storage; uses and access of stored dried bloodspots; and consent 
regarding storage and use of newborn bloodspots. The questionnaire responses were 
analysed using SPSS and descriptive statistics are presented. The Territories were not 
included in the survey because the administration of their NBS programs cross 
provincial boundaries. For example, the western area of the Northwest Territories is 
covered by Alberta and the eastern area by Manitoba. In Nunavut, the western area is 
covered by Manitoba and the eastern area by Québec and finally, the Yukon is 
covered by British Columbia.20 
 
c) Consultative Workshop 
 
To supplement information identified in the policy review and survey and to allow 
more in-depth understanding of the bioethical concerns on the storage issue for 
Canada’s NBS community, a consultative workshop was held in collaboration with 
the Garrod Association (www.garrod.ca). To foster a multidisciplinary dialogue about 
bioethical issues and to reflect different stakeholder experiences and perceptions, we 
brought together 40 individuals including representatives from provincial NBS 
laboratories, health professional associations, policy makers, consumer groups and the 
research community (Table I). Recruitment was carried out in collaboration with the 
Garrod Association of Canada organisers and the workshop was hosted at their 
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Table I. Representatives from Stakeholders Groups Invited to the Workshop 
 
Health Technology Assessment Agencies (AETMIS) 
Canadian Paediatrics Association 
Canadian Association of Paediatric Health Centres 
Children’s Hospital of Eastern Ontario 
Canadian Institute of Child Health 
Department of Epidemiology and Community Medicine, U. Ottawa 
Directors of Provincial Laboratories 
Health Canada 
Garrod Association Members 
National Council on Ethics in Human Research 
Save Babies Organisation 
Parent representing community groups 
 
 
A number of provincial lab directors, who had participated in the survey, were also 
included in the consultative meeting. The participants were not expected to achieve 
consensus. Audio-recording was not possible; however, detailed notes of the 
workshop discussion were taken by three research assistants and principal 
investigators in the research team (DA, HV, CG). The notes were used to describe the 
ethical, social and legal views expressed when discussing newborn bloodspot storage 




Ethical approval was requested and obtained from the Research Ethics Committee of 
the University of Montreal. Ethical approval was not required for the consultative 





We draw our analysis from the review of policy statements provided by the NBS 
programs, the description of the survey results and from the consultative workshop. 
 
a) Written Policies Relating to Newborn Screening and Storage 
 
Five provinces have written policies that relate to NBS: British Columbia, Alberta, 
Manitoba, Québec and New Brunswick. These policies differ widely in content and 
detail and variably address the purpose or goals of NBS in their guidelines for the 
collection, transportation and storage of samples, reporting requirements, follow-up 
procedures, and protocols for access to the bloodspots. 
 
Most provinces do not address the specific issue of long term storage of their newborn 
bloodspots. In fact, only Québec’s and Manitoba’s policies directly address length of 
storage. The Québec policies specify that samples are to be disposed of after one year 
unless the screening reveals an abnormality, in which case the sample is placed in a 
zip-lock bag and stored frozen.22 Manitoba’s policy includes a specific protocol for 
the storage of bloodspots for Duchene muscular dystrophy screening (which are 
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stored for a period of ten years); the remainder of the samples must be stored 
indefinitely (Protocol 3 B).23 Alberta’s and New Brunswick’s policies do not 
specifically address storage or future use of the samples.24 
 
Only British Columbia and Manitoba provide guidelines on access/future use of the 
stored samples. Manitoba has a protocol for the distribution of bloodspots for 
approved research projects,25 which specifies that bloodspots will only be available 
for research once all metabolic screening tests have been performed and the 
recommended waiting period for retesting has elapsed (II B.2.a).26 It also specifies 
measures to be taken to protect patient privacy: 
 
Blood spot samples will be assigned a different number than the 
CPL accession number with a Master List to be kept confidential 
and only stored at CPL. If a study is linked, linking to determine the 
identity of individual will be done by [a specified individual]. 
Researchers will not have access to the Master List. The follow up 
procedure for patients identified in linked studies must be approved 
by the Ethics Committee and the Manitoba Screening Committee (II 
B.2.b)27 
 
British Columbia’s policy deals with the ‘Retention and Ownership of Specimens’ but 
is not specifically conceived for newborn dried bloodspots.28 In terms of access, the 
policy provides that material may only be released to third parties for research, 
teaching or study where the approval of the Program Director or Department Head has 
been obtained (Policy 3.7).29 To protect patient confidentiality, no personal 
information may be disclosed without consent and all patient identifiers must be 
removed from specimens used for establishing norms or for other testing (Policy 
3.6).30 Future uses of the samples are addressed in the following provision: 
 
Body fluids which were collected for diagnostic purposes and which 
are intended to be discarded are considered abandoned and may be 
used for QA testing, determining normal values and other quality 
assurance activities such as method development and enhancement. 
However, patients should be advised at the time of their original 
consent for surgical/diagnostic procedures that “leftover” blood or 
body fluids may at some time be used for research, teaching or 
study. In the event that it is impossible/impractical to obtain consent 
for research/education use of left over specimens, the Ethics 
Committee approval must be given to proceed without fully informed 




For the purposes of the current paper, only the survey responses of the provincial 
laboratory directors or their delegates will be reported. The survey results will be 
described under the following topics: i) length and purpose of residual bloodspots 
storage, ii) use of and access to residual bloodspots, and iii) consent for storage. 
 
i) Duration and purpose of storage 
The survey results demonstrate that there is currently no consistency between 
provinces as to length of storage of newborn bloodspots. Indeed, duration of 
storage varies significantly from province to province, ranging from one to more 
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than 21 years. Québec, Newfoundland and Nova Scotia store bloodspots for one 
to five years; British Columbia and Alberta store them for five to ten years; 
whereas Saskatchewan, Manitoba, Ontario and New Brunswick store them for 
more than 21 years (Table II). The vast majority of provinces store the samples 
using personal identifiers. But, Manitoba and Québec have provided additional 




Table II. Duration and type storage of dried spots samples across Provinces 
 
Province Duration of storage (years) Type of storage 
British Columbia  5-10 yrs Identified 
Alberta 5-10 yrs Identified 
Saskatchewan >21 yrs Identified 
Manitoba > 21 yrs Single-coded 
Ontario 12-21 yrs Identified 
Québec 1 yr Double-coded 
Newfoundland 1-5 yrs Identified 
Prince Edward Island 1-5 yrs Identified 
Nova Scotia 5 yrs Identified 
New Brunswick > 21 yrs N/A 
 
 
Table III illustrates the most frequently cited purposes for storing residual 
bloodspots, with the most common reasons being: quality assurance, retesting to 
confirm results, and post-mortem diagnosis. Less commonly, bloodspots are 
stored for the purpose of developing and validating new tests, epidemiological 
research, and special family studies. Public health research, other medical 
research, and future DNA testing were infrequently cited as reasons for storage. 
Forensic studies were not identified by any province as a reason for storage. 
 
 
Table III. Reasons for storage of residual bloodspots 
 
Purpose Frequency 
Retesting to confirm test results 8 
Quality assurance 8 
Post-mortem diagnosis 6 
Develop & validate tests 5 
Epidemiological research 4 
Special family studies 4 
Public health research 3 
Other medical research 3 
Future DNA testing 2 
Forensic studies 0 
 
 
The responses to the question “Are there any costs associated with bloodspot 
storage?” revealed a range of estimates and uncertainties. In some provinces, the 
cost factor was unknown; others described the cost as ‘minimal’ or ‘quite 
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significant.’ One respondent suggested there is a need to take into consideration 
storage space, monitoring of environmental conditions and security levels, 
privacy and quality assurance standards when determining cost.  
 
ii) Uses of /access to dried bloodspots 
As mentioned in the policy review, British Columbia and Manitoba are the only 
provinces where written policies exist for the use of, or access to, residual 
specimens. Nevertheless, processes were reported to exist for the release of 
dried bloodspots from other provincial laboratories for various purposes (Table 
IV). Of note, the provincial laboratory had formal processes in place for the 
release for research purposes, medico-legal uses, and forensic purposes in five 
provinces, whereas three provinces have a process for release for quality 
assurance. Procedures were also reported to exist for the use of newborn 
bloodspots within the provincial laboratory to validate a method or establish 
levels of confidence (five provinces), to evaluate new technologies (four 
provinces), and for new DNA/RNA analysis (one province). 
 
When asked for what purposes bloodspots have been requested, respondents 
reported that bloodspots had been requested for post mortem diagnosis in 6 
provinces, for epidemiological research in four provinces, for future DNA 
diagnostic testing in three provinces, for other medical research in two 
provinces, for public health research in one, and for special family studies in 
one. No provinces report requests for release of dried bloodspots for forensic or 
legal research (such as victim identification or non-paternity testing). (Table III) 
 
 
Table IV. Does the provincial laboratory have a process for the release of dried 
bloodspots? 
 
Uses BC ALTA SASK MAN ON QC NFLD PEI NS NB 
Research Y Y N Y Y Y N Y Y N 
Medico-Legal Y Y N N Y Y N Y Y N 
Forensic Y Y N N Y Y N Y Y N 
Quality Assurance Y Y N N Y Y N N Y N 
 
 
iii) Consent for storage and use 
None of the provinces require written consent for the storage of dried 
bloodspots. Consent to storage is generally implicit, but parents are nevertheless 
free to opt out of storage in all provinces other than Manitoba. It is worth 
noting, however, that only in British Columbia and Nova Scotia are parents 
given written information that the child’s screening sample will in fact be stored 
(Table V). 
 
Only three of the provincial laboratories require parental written consent prior to 
use of newborn bloodspots for secondary purposes (Québec, Ontario and 
Saskatchewan). In no province are donors asked to provide renewed consent once 
they have reached the age of majority (Ontario was unclear on this). It must be 
noted, however, that only four provinces currently retain bloodspots for long 
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Table V. Consent and storage policies by province 
 
 
Questions BC ALTA SAS MAN ON QC NFL PEI NS NB 
Are the hospitals required 
to obtain written consent 
for the storage of dried 
bloodspots?  
N N N N N N N N N N 
Are parents given any 
written information that 
the child’s screening 
sample will be stored? 
N N N/A N/A N/A N/A N/A N N N/A 
Does the laboratory 
require written parental 
consent prior to use of 
residual specimens? 
N N Y N Y Y N N N N 
Is explicit written consent 
a requirement for uses of 
newborn bloodspots for 
others purposes? 
N N Y N Y Y N/A N N N/A 
Does the NBS program 
have any written policies 
with regards to bloodspots 
storage? 
N N N/A N N/A N N/A N N NA 
Does the provincial 
laboratory have a written 
policy for the use of 
residual specimens? 
Y N N Y N N N Y Y N 
Can parents request access 
or destruction of stored 
samples? 
Y Y Y N/A N/A Y N/A Y Y Y 
 
c) Consultative Workshop 
 
In order to address the concerns about the storage of newborn bloodspots all 
participants were asked to consider three central issues: i) the appropriate length of 
storage; ii) uses and access; iii) the nature of the consent required for secondary uses. 
 
i) Duration and purposes of storage 
Much of the discussion in the group was centered on short vs. long term storage 
issues. Participants explored the rationale underlying short as opposed to long term 
storage. It seems that the traditional benchmark of five years is based on the 
assumption that most metabolic diseases will manifest within this time. In Québec, 
samples are routinely stored for only one to two years because this is thought to 
provide sufficient time for confirmatory tests in normal cases; abnormal samples are 
stored for a longer period. Another reason to limit storage time is that the quality of 
the sample deteriorates over time, especially if not stored under ideal conditions. 
Finally, the fact that consent is presumed was cited as a factor supporting a shorter 
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storage time. Specific rationale for storing samples for extended periods of time 
were not voiced, but, presumably, the length of storage will be directly related to the 
anticipated future uses of the samples. It was noted that the length of storage and the 
types of uses envisioned will determine to a great extent the nature of the consent 
required. 
 
As storage duration increases, the costs of storage will also increase. It seems that the 
costs of adequate storage can be quite significant. Storage costs will therefore likely 
be factored into policy making around the appropriate length of storage for 
bloodspots. One solution proposed to eliminate provincial disparities with respect to 
storage was the creation of a central repository: blood samples could be stored by the 
provinces for the initial five-year period and subsequently sent to a central repository 
for use in research. 
 
ii) Uses of/access to dried bloodspots 
Overall, the respondents discussed the potential value of NBS bloodspots for research. 
However, there was less general support for other purposes such as DNA diagnostic 
testing, post-mortem analysis, special family studies, forensic studies, etc. It was 
agreed that there may be appropriate and inappropriate secondary uses of newborn 
dried bloodspots although there was diversity on where to draw the line and how to 
proceed. All participants concurred, nonetheless, that if the samples are to be used for 
secondary purposes, these uses should not interfere in any way with the primary 
purposes of NBS. It was also common ground that secondary uses should be 
congruent with existing ethical guidelines. 
 
The discussion focussed primarily on the secondary use of dried bloodspots for 
research purposes. There was a general, if not unanimous sentiment that use for 
research may be permissible in certain circumstances. The respondents felt that as 
long as identifiers have been removed in accordance with the Tri-Council Policy 
Guidelines32 and the American Academy of Pediatrics33 amongst others, then 
researchers should be allowed to use the bloodspots. The Tri-Council Policy, for 
example, provides that if the data within a database are anonymous/non-identifying, 
then researchers should be allowed to use that database (section 3.3). Because 
research projects generally require research ethics board (REB) approval, it was 
recognised that research protocols will automatically be subject to review and 
inappropriate uses will presumably be denied. Some felt that both the Tri-Council 
Policy statement and the review by REBs provide sufficient safeguards.  
 
However, workshop participants were also concerned about the proficiency of the 
REBs to determine appropriate research uses, especially where the proposed research 
is complex. It was noted that REBs’ interpretations and standards vary from board to 
board and decisions therefore appear arbitrary. Participants suggested, as a safeguard, 
the creation of a council with the stem cell research model in mind, where CIHR’s 
Stem Cell Oversight Committee (SCOC) must approve research projects involving 
human stem cells before granting funding to an institution, prior to and in addition to 
REB approval.34 Under this model, complex research projects would first have to be 
approved by this national panel of experts before being submitted to the local REB. 
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Concern about the use of newborn dried bloodspots for forensic purposes was also 
discussed. While at least one participant felt that storage and use of samples for future 
forensic purposes was justifiable from a public policy perspective, the majority 
believed that such use would violate our country’s tradition of individual liberties. 
The use of newborn bloodspots for forensic purposes was said to be equivalent to 
fingerprinting everyone in the country. Most agreed that we should be cautious about 
taking that route because of the potential misuse. 
 
iii) Consent for storage and use 
The discussion centred on the more contentious issue of whether consent should be 
required for secondary uses of stored samples. There was no consensus as to whether 
informed consent, be it of a general or specific nature, should be obtained before 
newborn dried bloodspots may be used in research. The issue of whether informed 
consent is required can vary depending on the type of research and the degree of 
anonymity. Many participants felt that when samples are anonymized and submitted 
to an ethics board for review, research can be conducted without explicit consent. It 
was recognised that anonymization may entail ethical problems where the research 
detects something that is of relevance to the health of the individual, since the origin 
of the sample cannot be traced and so the patient cannot be informed. 
 
Given the very small number of parents who opt out of screening programs, some 
questioned the necessity of obtaining consent for research purposes. However, it was 
suggested that an evaluation of refusal rates could be carried out. If only a negligible 
proportion of parents are found to refuse, then the consent requirement could be 
dispensed with. This type of reasoning has been applied in Manitoba where written 
consent was originally required for use of bloodspots in research, but because nobody 
ever refused, the REB allowed the written consent to be dropped.35 
 
Another concern was raised with respect to obtaining explicit informed consent for 
secondary uses. It was felt that were explicit informed consent to become a 
requirement due to the use of the samples for various secondary purposes, 
participation rates in screening programs on the whole may be negatively affected. If 
this were the case, then the primary purpose of the screening would be impaired. This 
could be seen as a justification for not requiring explicit consent and relying instead 
on anonymization and ethics board approval. It was noted, however, that the 
elimination of a consent requirement on the basis of a sample of public opinion may 
not be defensible in this era of increasing recognition of individual autonomy and 
privacy rights, and more so, in light of the CIHR Guidelines for Human Pluripotent 
Stem Cell Research, where parental consent is a requirement in any research 
involving human stem cells derived from a newborn’s umbilical cord. 
 
A different issue that was discussed is parental wishes to be informed about storage. 
Regardless of whether consent is implied or explicit, there was consensus that parents 
should be informed about the screening program in general. Participants also 
indicated the need for information about possible future use of the samples, and about 
the intended duration of storage. Information on NBS is generally provided to parents 
in written form as part of a prenatal package and/or at the time of birth. In some 
provinces, such as Québec, this information includes the length of storage.  
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However, the participants questioned whether written information was actually read 
and understood by parents. The Québec experience relating to additional screening of 
urine indicates that brochures can be effective in conveying this sort of information. 
Information on this additional screening program is provided to parents in brochure 
form and parents are required to take the initiative to send the urine samples in 
themselves. 89% of parents in Québec sent back their child’s urine sample; this 





This review provides descriptive information about the provision of newborn 
screening program policy for bloodspot storage and uses of stored samples by 
surveying Directors of NBS programs and consulting multiple stakeholders. In light 
of the growing interest in newborn bloodspots and considering the potential health 
benefits that could emerge from research using bloodspots, proactive solutions should 
be entertained to ensure proper protection and choice.37 
 
As revealed by the survey and consultation workshop, there is a lack of uniformity in 
provincial approaches to storage of dried bloodspots, uses and access, and the amount 
of information given to parents about storage. Most provinces do not have written 
policies on the specific issue of long-term storage of newborn bloodspots. However, 
some provincial NBS programs (3 out of 10) had policies regarding storage. About 
half of the provincial programs indicated they had some formal measures in place for 
the release of bloodspots for research, medico-legal and forensic purposes. 
 
Our findings are consistent with other studies demonstrating variability in 
practices.38,39 One of the changes that has taken place on the international scene has 
been the development of recommendations that provide a national framework of 
principles and procedures to address the retention of newborn bloodspots and their 
secondary use.40,41,42,43 The variations in provincial policies testify to the need for
common standards in Canada. The development of such policies requires a 
consultative process. Traditionally, NBS programs were decided administratively by 
the health department with little or no input from the public.
 
44 However, today, 
openness, collaboration and partnership have become the norm, and it is accepted that 
a range of stakeholders should participate.45 Stakeholders in the NBS community 
include the directors of laboratories, policy makers, clinicians, patients, public 
representatives and other related communities that have a stake in defining NBS 
policies. While there is a need to develop written policies for retention, usage and 
release of dried bloodspots, such policies should be developed and endorsed in 
consultation with these stakeholders in a manner that fosters multidisciplinary and 
pluralistic dialogue46 and introduces a broad social consensus.47 Moreover while the 
cost estimate of storing NBS was brought up by one participant and is an important 
issue we did not set up our research question to address or discuss this topic in greater 
detail. There are many components that need to be integrated into this cost estimate 
including storage, quality control and transportation variables. 
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Overall while no specific recommendations were generated by the working group 
meeting at the Garrod Association annual meeting, the workshop provided the 
groundwork for further discussions and policy development in this area. 
 
Reasons for storage include non-controversial purposes such as for laboratory audit, 
the development of new tests or for confirming a diagnosis. However, these reasons 
represent only one component of the uses. Samples could also be used for research 
purposes. Overall, there was considerable support for, and recognition of the notion 
that dried blood samples are a valuable resource for medical research, and that their 
use should be carefully managed with appropriate safeguards. The survey data 
regarding access and further uses of cards indicated that the primary uses of the stored 
bloodspots were for the screening program and that other uses of NBS cards rarely 
occurred. Similarly, during the consultation workshop it was recognised that although 
newborn bloodspots constitute valuable research tools, the storing of bloodspots 
should not hinder the primary screening purpose of the NBS program. While storage 
of NBS was seen as a factor that argues against the justification for epidemiological 
research, it has been shown that NBS are especially useful for research that will 
provide considerable health benefits for children. 48,49 
 
The secondary use of NBS cards also raises ethical challenges regarding the 
protection of privacy and confidentiality. In fact, the survey revealed that the cards 
were occasionally stored with their identifiers and at other times were anonymized. 
The participants in the consultative workshop indicated that research can be 
conducted as long as identifiers are removed and REB approvals are consistent with 
the guidelines set by the Tri-Council’s report.50 Moreover it would appear from a 
survey51 in Australia, that the public is supportive, considering over 85% of the cohort 
of new mothers believed that anonymised samples should be made available for 
research. However, the question of anonymisation raises important ethical concerns 
since the research findings may detect relevant health information for the infant, yet 
because of the de-identification there is no way of tracing the individual. To improve 
the usefulness of the archived materials, more and more double-coding has emerged 
as a tool which promotes confidentiality and ongoing research.52 
 
While informed consent is considered relevant to the storage and use of dried 
bloodspots, and while parents have a right to be informed of this occurrence,53 our 
survey and workshop could not pinpoint whether explicit consent to future use of 
bloodspots should be obtained, and if so, whether that should take place at the time of 
collection or at the time they are requested for research purposes. An overview of the 
importance of informed consent for research with biological samples reveals 
disagreement on the type of consent that is needed.54 It has recently been suggested 
that if at the time of collection, bloodspots are intended to be used in a research 
project, that written consent be sought at the time of collection; if no particular 
research is foreseen, written consent would need to be obtained in the absence of 
anonymisation.55 For some types of research (ie, longitudinal or disease oriented), a 
system of coding or double-coding combined with parental consent may be more 
appropriate. Yet, overall there appears to be no consensus as to whether an explicit 
informed consent should be required for secondary uses. However, anonymisation and 
ethics board approval without explicit consent may be sufficient for research 
purposes.56 Concerns raised by the workshop participants over the variability in 
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approaches by different REBs are also reflected in the literature.57 However since 
there are many potential benefits to be gained from using NBS for epidemiological 
research, it can be argued that research without explicit consent is worthwhile if 
proper mechanisms are in place to protect individual information from improper use. 
It is important to note that a new trend is emerging whereby individual ethics of 
privacy and immediate personal benefit are traded for the benefit of others including 
future others.58 
 
Closely associated with consent is the need for better information about the consent 
process and of the informational material provided to parents to obtain their 
permission.59 When should parents be informed about newborn screening? What type 
of information should be provided? Because the information might matter to the child, 
how and when should relevant information be conveyed to children? It has been 
proposed that prior to birth, and whether or not explicit consent for screening is 
required, information should be made available to parents regarding the following: 
purpose, duration and method of storage, potential uses of residual samples, 
possibility or impossibility of being re-contacted, possibility or impossibility of 
receiving research results, ownership of samples, access to residual bloodspots and 
right to refuse storage or to withdraw.60 Challenges that may impede understanding 
include language barriers and variation in educational levels. The points of view of 
parents also need to be further researched. Finally, concerns about costs associated 
with providing security to prevent unauthorised use, disclosure, loss or other misuse 
need to be evaluated. 
 
A potential limitation of this study is the small sample size. We sought information 
from laboratory directors and a sample of representative stakeholders regarding the 
social, ethical and legal aspects of the retention storage, access and further uses of 
NBS bloodspots. While the consultation workshop is an obvious attempt to obtain a 
broad-based representation, there is a need for broader consultation with respondents 
from other areas of Canada. To ensure a broader representation, we suggest similar 
consultative workshops in each province and territory as they develop their policies 
regarding the storage of newborn bloodspots. 
 
Another obvious limitation is that a survey with closed-ended answers limits our 
understanding of the existing context of the policy process. As indicated, there are 
processes in place for the release of dried bloodspots from provincial laboratories for 
various purposes. Notably, five provincial laboratories had formal processes in place 
for the release of bloodspots for research, medico-legal and forensic purposes. 
Interviews with the key respondents in each province would provide real-life personal 





In this study, we have identified a lack of written policies and procedures in several 
Provincial newborn screening programs across Canada in relation to the storage and 
potential future use of stored bloodspots. In accordance with standard laboratory 
practice, policies and procedures need to be explicit and transparent. Considering the 
sensitive nature of the information that can be derived from bloodspots, there is a need 
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for heightened transparency and clear policies concerning the criteria and length of 
storage, as well as permissible secondary uses of dried bloodspots. 
 
Presently, there is no national newborn screening organisation to address national 
standards in Canada. Achieving a national consensus will require a commitment from 
both provincial and federal stakeholders. Consequently, it would be valuable to have 
an established forum for the development of comprehensive policies that would 
include the issues described above. The Garrod association, which is a professional 
body that promotes the prevention, diagnosis and management of hereditary metabolic 
disease, has been instrumental in the development of national guidelines. Existing 
national professional bodies with an interest in metabolic medicine and newborn 
screening, in conjunction with other stakeholders, would be well-suited to tackle 
issues related to newborn screening at the national level.  
Lessons learned from this experience testify that: 
• the variations in policies across the country are clearly a challenge; 
• the workshop serves as a launching pad for both further discussion and a 
national policy development in this area; 
• despite the broad interests and multiple disciplines of participants, there is a 
remarkable uniformity in terms of commitment to the development of 
newborn bloodspot collection and storage policies across Canada; 
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